Cited by 107Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCholangiocarcinoma and Gallbladder Cancer Studies

Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival

Shin, Sang Hyun, Kim, Song Cheol, Hong, Seung-Mo, Kim, Young Hoon, Song, Ki-Byung, Park, Kwang-Min, Lee, Young-Joo·2013·Pancreas

Abstract

OBJECTIVES: The objective of this study was to evaluate genetic alterations of K-ras, p53, c-erbB-2, and deleted in pancreatic cancer, locus 4 (DPC4) genes in pancreatic ductal adenocarcinoma and correlate these changes with patients' overall survival. METHODS: Between April 2004 and December 2008, 272 patients with pancreatic ductal adenocarcinoma underwent surgical resection at a single institute. Genetic analyses and immunohistochemical stains were reviewed retrospectively. RESULTS: Alterational rates of each gene were as follows: K-ras, 53.8%; p53, 38.2%; c-erbB-2, 7.3%; DPC4, 81.6%. Subtypes of K-ras gene were as follows: GGT (wild type), 46.2%; GAT, 31.2%; GTT, 14.5%; CGT, 5.6%; TGT, 1.7%; CTG, 0.4%; AGT, 0.4%. K-ras mutation (especially GAT subtype) and DPC4 inactivation resulted in a reduction of postresection survival (P = 0.001 and P = 0.047). Univariate analysis revealed 8 factors affecting to the survival, and multivariate analysis revealed that 6 of them were independently responsible for poor survival of patients: presence of lymphovascular tumor emboli, DPC4 inactivation, poorly differentiated carcinoma, K-ras mutation, presence of lymph node metastasis, and elevated CA-19-9 (>37 U/mL). CONCLUSIONS: This study may help to understand the genetic feature of pancreatic cancer and its survival effect in our population. This shows that additional genetic insights would contribute to the improvement of patients' prognosis.

Integrity signals

Registry

Crossref · 10.1097/mpa.0b013e31825b6ab0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SMAD4 loss is associated with distant metastases.

    “Notably, SMAD4 loss is associated with distant metastases, highlighting its role in disease progression patterns [72,73,74,75,76,118].”
  • Patients with DPC4-expressed cancers exhibit longer survival.

    “Patients with DPC4-expressed cancers exhibit longer survival, emphasizing the significance of SMAD4 in treatment outcomes.”
  • DPC4 gene frequently experiences inactivation in PDAC, leading to enhanced metastasis and worse prognosis.

    “The DPC4 gene, encoding SMAD4, frequently experiences inactivation in PDAC, leading to enhanced metastasis and worse prognosis.”
  • In localized and resectable PDAC, KRAS mutation has been found either negatively associated or not associated with survival.

    “For example, in localized and rescetable PDACs, KRAS mutation was found to be either negatively associated with or not associated with survival (59, 60).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [59]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Shin, S. H., Kim, S. C., Hong, S.-M., Kim, Y. H., Song, K.-B., Park, K.-M., & Lee, Y.-J.
Affiliations
Asan Medical Center (KR)
Corresponding author
  • Shin, Sang Hyun
  • Kim, Song Cheol
  • Kim, Young Hoon
  • Song, Ki-Byung
  • Park, Kwang-Min
Venue
Pancreas
Published
2013-03
Volume
42
Issue
2
Pages
216-222
ISSN
0885-3177 (ISSN-L)
OpenAlex
W1986779145
Cited by
107
References
2
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 17 · 2016: 14 · 2015: 8 · 2014: 9 · 2013: 8
FWCI
6.96
Type
journal article
Language
en
Open access
closed
Locations
  • Pancreas (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
pancreatic ductal adenocarcinoma, KRAS mutation, p53, c-erbB-2, tumor suppressor, prognostic factors, overall survival, lymph node metastasis, CA19-9, tumor differentiation
MeSH terms
Adult, Aged, DNA Mutational Analysis, Female, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Phenotype, Prognosis, Proto-Oncogene Proteins, Retrospective Studies, Risk Factors, Time Factors, Biomarkers, Tumor, Multivariate Analysis, Proportional Hazards Models, Odds Ratio, Polymerase Chain Reaction, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), CA-19-9 Antigen, Risk Assessment, ras Proteins, Erb-b2 Receptor Tyrosine Kinases, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, Smad4 Protein, Kaplan-Meier Estimate, Young Adult, Republic of Korea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review